title: Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
authors.forename: Marjorie
authors.initials: M
authors.lastname: Hilbert
authors.forename: Pierre
authors.initials: P
authors.lastname: Mary
authors.forename: Michelle
authors.initials: M
authors.lastname: Larroquet
authors.forename: Marie-Odile
authors.initials: MO
authors.lastname: Serinet
authors.forename: Sylvie
authors.initials: S
authors.lastname: Helfre
authors.forename: Herve
authors.initials: H
authors.lastname: Brisse
authors.forename: Aurore
authors.initials: A
authors.lastname: Coulomb
authors.forename: Daniel
authors.initials: D
authors.lastname: Orbach
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D011758:Pyrroles / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D018234:Sarcoma, Alveolar Soft Part / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D020794:Receptor Protein-Tyrosine Kinases; D000077210:Sunitinib